Video

Sanjiv Chopra, MD: How to Treat NAFLD

Author(s):

NAFLD is currently the most prevalent liver disease in the US.

There are many things that can be said about the overall health of Americans, but really for many everyday life is littered with health problems.

With obesity and diabetes rates increasing in recent years, the rates for non-alcoholic fatty liver disease (NAFLD) might be at an all-time high.

And this increase in disease rates can be seen in patients of all ages, from as young as 3 to senior citizens.

This increase is also coupled with the fact that there is not currently a treatment approved by the US Food and Drug Administration (FDA).

But there are ways to prevent or reduce the odds of NAFLD and help could be on the way.

In an interview with HCPLive®, Sanjiv Chopra, MD, Professor of Medicin, Harvard Medical School, said losing weight and drinking 2-3 cups of coffee daily could help reduce the risk of NAFLD.

But the current state of affairs is not good.

“We have 3 year old’s in our country with fatty liver,” Chopra said. “We have 16 year old’s with liver scaring, we have 28-30 year old’s getting a liver transplant. It’s a sad commentary on what’s happened to us with our lifestyle.”

And while there is a push for a healthier overall lifestyle, there also may be finally a treatment coming for NAFLD.

Chopra said there is currently 452 clinical trials involving the disease and an FDA-approved drug could come by the end of the year.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.